The International Consensus in Time in Range (TIR) was recently released and defined the concept of the time spent in the target range between 70 and 180 mg/dL while reducing time in hypoglycemia, for patients using Continuous Glucose Monitoring (CGM). TIR was validated as an outcome measures for clinical Trials complementing other components of glycemic control like Blood glucose and HbA1c. The challenge is to implement this practice more widely in countries with a limited health public and private budget as it occurs in Brazil. Could CGM be used intermittently? Could self-monitoring blood glucose obtained at different times of the day, with the amount of data high enough be used? More studies should be done, especially cost-effective studies to help understand the possibility of having sensors and include TIR evaluation in clinical practice nationwide.
CITATION STYLE
Gabbay, M. A. L., Rodacki, M., Calliari, L. E., Vianna, A. G. D., Krakauer, M., Pinto, M. S., … Pedrosa, H. P. C. (2020, March 16). Time in range: A new parameter to evaluate blood glucose control in patients with diabetes. Diabetology and Metabolic Syndrome. BioMed Central Ltd. https://doi.org/10.1186/s13098-020-00529-z
Mendeley helps you to discover research relevant for your work.